{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:27:05Z","timestamp":1790126825676,"version":"4.0.1"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI123321"],"award-info":[{"award-number":["AI123321"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI138139"],"award-info":[{"award-number":["AI138139"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI152220"],"award-info":[{"award-number":["AI152220"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI136118"],"award-info":[{"award-number":["AI136118"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016230","name":"Steven and Alexandra Cohen Foundation","doi-asserted-by":"publisher","award":["Lyme 62 2020"],"award-info":[{"award-number":["Lyme 62 2020"]}],"id":[{"id":"10.13039\/100016230","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014731","name":"Global Lyme Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Human babesiosis is a potentially fatal tick-borne disease caused by intraerythrocytic Babesia parasites. The emergence of resistance to recommended therapies highlights the need for new and more effective treatments. Here we demonstrate that the 8-aminoquinoline antimalarial drug tafenoquine inhibits the growth of different Babesia species in vitro, is highly effective against Babesia microti and Babesia duncani in mice and protects animals from lethal infection caused by atovaquone-sensitive and -resistant B. duncani strains. We further show that a combination of tafenoquine and atovaquone achieves cure with no recrudescence in both models of human babesiosis. Interestingly, elimination of B. duncani infection in animals following drug treatment also confers immunity to subsequent challenge. Altogether, the data demonstrate superior efficacy of tafenoquine plus atovaquone combination over current therapies for the treatment of human babesiosis and highlight its potential in providing protective immunity against Babesia following parasite clearance.<\/jats:p>","DOI":"10.1093\/infdis\/jiad315","type":"journal-article","created":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T14:52:40Z","timestamp":1704293560000},"page":"161-172","source":"Crossref","is-referenced-by-count":34,"title":["Tafenoquine-Atovaquone Combination Achieves Radical Cure and Confers Sterile Immunity in Experimental Models of Human Babesiosis"],"prefix":"10.1093","volume":"229","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4944-6006","authenticated-orcid":false,"given":"Pratap","family":"Vydyam","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, School of Medicine, Yale University , New Haven, Connecticut , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anasuya C","family":"Pal","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, School of Medicine, Yale University , New Haven, Connecticut , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaline","family":"Renard","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, School of Medicine, Yale University , New Haven, Connecticut , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenal","family":"Chand","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, School of Medicine, Yale University , New Haven, Connecticut , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vandana","family":"Kumari","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, School of Medicine, Yale University , New Haven, Connecticut , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph C","family":"Gennaro","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, School of Medicine, Yale University , New Haven, Connecticut , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choukri Ben","family":"Mamoun","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, School of Medicine, Yale University , New Haven, Connecticut , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,3]]},"reference":[{"key":"2024011216395806300_jiad315-B1","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/S0020-7519(00)00137-5","article-title":"Human babesiosis: an emerging tick-borne disease","volume":"30","author":"Kjemtrup","year":"2000","journal-title":"Int J Parasitol"},{"key":"2024011216395806300_jiad315-B2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ijpara.2018.11.007","article-title":"Human babesiosis","volume":"49","author":"Krause","year":"2019","journal-title":"Int J Parasitol"},{"key":"2024011216395806300_jiad315-B3","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.3201\/eid2408.180180","article-title":"Misdiagnosis of babesiosis as malaria, Equatorial Guinea, 2014","volume":"24","author":"Arsuaga","year":"2018","journal-title":"Emerg Infect Dis"},{"key":"2024011216395806300_jiad315-B4","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.pt.2007.09.005","article-title":"Shared features in the pathobiology of babesiosis and malaria","volume":"23","author":"Krause","year":"2007","journal-title":"Trends Parasitol"},{"key":"2024011216395806300_jiad315-B5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.15585\/mmwr.mm7211a1","article-title":"Trends in reported babesiosis cases\u2014United States, 2011\u20132019","volume":"72","author":"Swanson","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024011216395806300_jiad315-B6","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1056\/NEJMra1202018","article-title":"Human babesiosis","volume":"366","author":"Vannier","year":"2012","journal-title":"N Engl J Med"},{"key":"2024011216395806300_jiad315-B7","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/cid\/ciab050","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America (IDSA): 2020 guideline on diagnosis and management of babesiosis","volume":"72","author":"Krause","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024011216395806300_jiad315-B8","doi-asserted-by":"crossref","DOI":"10.1016\/j.idcr.2018.e00414","article-title":"Fatal human babesiosis caused by Babesia divergens in an asplenic host","volume":"13","author":"Kukina","year":"2018","journal-title":"IDCases"},{"key":"2024011216395806300_jiad315-B9","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.3201\/eid2408.180309","article-title":"Probable locally acquired Babesia divergens-like infection in woman, Michigan, USA","volume":"24","author":"Herc","year":"2018","journal-title":"Emerg Infect Dis"},{"key":"2024011216395806300_jiad315-B10","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41564-023-01360-8","article-title":"Babesia duncani multi-omics identifies virulence factors and drug targets","volume":"8","author":"Singh","year":"2023","journal-title":"Nat Microbiol"},{"key":"2024011216395806300_jiad315-B11","doi-asserted-by":"crossref","first-page":"375","DOI":"10.7589\/0090-3558-42.2.375","article-title":"Molecular characterization of a babesia species identified in a north American raccoon","volume":"42","author":"Birkenheuer","year":"2006","journal-title":"J Wildl Dis"},{"key":"2024011216395806300_jiad315-B12","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.3390\/pathogens10091120","article-title":"Treatment of human babesiosis: then and now","volume":"10","author":"Renard","year":"2021","journal-title":"Pathogens"},{"key":"2024011216395806300_jiad315-B13","doi-asserted-by":"crossref","DOI":"10.1016\/j.idcr.2022.e01460","article-title":"Use of tafenoquine to treat a patient with relapsing babesiosis with clinical and molecular evidence of resistance to azithromycin and atovaquone","volume":"27","author":"Marcos","year":"2022","journal-title":"IDCases"},{"key":"2024011216395806300_jiad315-B14","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.3390\/pathogens11091051","article-title":"Failure of an approximately six week course of tafenoquine to completely eradicate Babesia microti infection in an immunocompromised patient","volume":"11","author":"Prasad","year":"2022","journal-title":"Pathogens"},{"key":"2024011216395806300_jiad315-B15","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1086\/649859","article-title":"Emergence of resistance to azithromycin-atovaquone in immunocompromised patients with Babesia microti infection","volume":"50","author":"Wormser","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2024011216395806300_jiad315-B16","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1093\/cid\/cix477","article-title":"Clinical and molecular evidence of atovaquone and azithromycin resistance in relapsed Babesia microti infection associated with rituximab and chronic lymphocytic leukemia","volume":"65","author":"Simon","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2024011216395806300_jiad315-B17","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1086\/593812","article-title":"Transfusion-transmitted babesiosis in Washington state: first reported case caused by a WA1-type parasite","volume":"175","author":"Herwaldt","year":"1997","journal-title":"J Infect Dis"},{"key":"2024011216395806300_jiad315-B18","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1046\/j.1537-2995.2002.00245.x","article-title":"Investigation of transfusion transmission of a WA1-type babesial parasite to a premature infant in California","volume":"42","author":"Kjemtrup","year":"2002","journal-title":"Transfusion"},{"key":"2024011216395806300_jiad315-B19","doi-asserted-by":"crossref","first-page":"284","DOI":"10.7326\/0003-4819-119-4-199308150-00006","article-title":"Babesiosis in Washington state: a new species of Babesia?","volume":"119","author":"Quick","year":"1993","journal-title":"Ann Intern Med"},{"key":"2024011216395806300_jiad315-B20","article-title":"First record of locally acquired human babesiosis in Canada caused by Babesia duncani: a case report","volume":"5","author":"Scott","year":"2017","journal-title":"SAGE Open Med Case Rep"},{"key":"2024011216395806300_jiad315-B21","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1056\/NEJM199502023320504","article-title":"Infection with a babesia-like organism in northern California","volume":"332","author":"Persing","year":"1995","journal-title":"N Engl J Med"},{"key":"2024011216395806300_jiad315-B22","article-title":"Severe babesiosis with heavy parasitemia in an immunocompetent patient treated successfully with red cell exchange transfusion","volume":"14","author":"Sanivarapu","year":"2022","journal-title":"Cureus"},{"key":"2024011216395806300_jiad315-B23","doi-asserted-by":"crossref","first-page":"19974","DOI":"10.1074\/jbc.AC118.005771","article-title":"Establishment of a continuous in vitro culture of Babesia duncani in human erythrocytes reveals unusually high tolerance to recommended therapies","volume":"293","author":"Abraham","year":"2018","journal-title":"J Biol Chem"},{"key":"2024011216395806300_jiad315-B24","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.20151519","article-title":"Radical cure of experimental babesiosis in immunodeficient mice using a combination of an endochin-like quinolone and atovaquone","volume":"213","author":"Lawres","year":"2016","journal-title":"J Exp Med"},{"key":"2024011216395806300_jiad315-B25","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.15585\/mmwr.mm6846a4","article-title":"Guidance for using tafenoquine for prevention and antirelapse therapy for malaria\u2014United States, 2019","volume":"68","author":"Haston","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024011216395806300_jiad315-B26","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s40265-018-0979-2","article-title":"Tafenoquine: first global approval","volume":"78","author":"Frampton","year":"2018","journal-title":"Drugs"},{"key":"2024011216395806300_jiad315-B27","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1128\/AAC.41.1.91","article-title":"Evaluation of selected antiprotozoal drugs in the Babesia microti-hamster model","volume":"41","author":"Marley","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"2024011216395806300_jiad315-B28","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s13071-020-04235-7","article-title":"Activities of artesunate-based combinations and tafenoquine against Babesia bovis in vitro and Babesia microti in vivo","volume":"13","author":"Carvalho","year":"2020","journal-title":"Parasit Vectors"},{"key":"2024011216395806300_jiad315-B29","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00204-21","article-title":"Tafenoquine is a promising drug candidate for the treatment of babesiosis","volume":"65","author":"Liu","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2024011216395806300_jiad315-B30","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/infdis\/jiz119","article-title":"Could the drug tafenoquine revolutionize treatment of Babesia microti infection?","volume":"220","author":"Mordue","year":"2019","journal-title":"J Infect Dis"},{"key":"2024011216395806300_jiad315-B31","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/cid\/ciac473","article-title":"Broad antimicrobial resistance in a case of relapsing babesiosis successfully treated with tafenoquine","volume":"76","author":"Rogers","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2024011216395806300_jiad315-B32","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3390\/pathogens11050599","article-title":"An alternative culture medium for continuous in vitro propagation of the human pathogen Babesia duncani in human erythrocytes","volume":"11","author":"Singh","year":"2022","journal-title":"Pathogens"},{"key":"2024011216395806300_jiad315-B33","doi-asserted-by":"crossref","first-page":"e4549","DOI":"10.21769\/BioProtoc.4549","article-title":"Babesia duncani in culture and in mouse (ICIM) model for the advancement of babesia biology, pathogenesis, and therapy","volume":"12","author":"Kumari","year":"2022","journal-title":"Bio Protocol"},{"key":"2024011216395806300_jiad315-B34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.00662-21","article-title":"Effective therapy targeting cytochrome bc(1) prevents Babesia erythrocytic development and protects from lethal infection","volume":"65","author":"Chiu","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2024011216395806300_jiad315-B35","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.3389\/fphar.2019.01222","article-title":"Isobologram analysis: a comprehensive review of methodology and current research","volume":"10","author":"Huang","year":"2019","journal-title":"Front Pharmacol"},{"key":"2024011216395806300_jiad315-B36","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s12936-017-1862-4","article-title":"The blood schizonticidal activity of tafenoquine makes an essential contribution to its prophylactic efficacy in nonimmune subjects at the intended dose (200 mg)","volume":"16","author":"Dow","year":"2017","journal-title":"Malar J"},{"key":"2024011216395806300_jiad315-B37","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/infdis\/jiac181","article-title":"Babesia duncani as a model organism to study the development, virulence and drug susceptibility of intraerythrocytic parasites in vitro and in vivo","volume":"226","author":"Pal","year":"2022","journal-title":"J Infect Dis"},{"key":"2024011216395806300_jiad315-B38","doi-asserted-by":"publisher","DOI":"10.1101\/2023.02.01.526700","article-title":"Spermidine is the main polyamine required by intracellular parasites for survival within host erythrocytes","author":"Singh","year":"2022","journal-title":"bioRxiv"},{"key":"2024011216395806300_jiad315-B39","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1021\/acsinfecdis.8b00113","article-title":"Evaluation of current and emerging antimalarial medicines for inhibition of Toxoplasma gondii growth in vitro","volume":"4","author":"Radke","year":"2018","journal-title":"ACS Infect Dis"},{"key":"2024011216395806300_jiad315-B40","doi-asserted-by":"crossref","first-page":"6151","DOI":"10.1128\/AAC.00879-15","article-title":"The oral antimalarial drug tafenoquine shows activity against Trypanosoma brucei","volume":"59","author":"Carvalho","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2024011216395806300_jiad315-B41","first-page":"1","article-title":"Tafenoquine: a 2018 novel FDA-approved prodrug for the radical cure of Plasmodium vivax malaria and prophylaxis of malaria","volume":"115","author":"Mayence","year":"2019","journal-title":"Pharmaceuticals (Basel)"},{"key":"2024011216395806300_jiad315-B42","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa1802537","article-title":"Tafenoquine versus primaquine to prevent relapse of Plasmodium vivax malaria","volume":"380","author":"Llanos-Cuentas","year":"2019","journal-title":"N Engl J Med"},{"key":"2024011216395806300_jiad315-B43","doi-asserted-by":"crossref","first-page":"200","DOI":"10.7326\/0003-4819-88-2-200","article-title":"Failure of chloroquine in human babesiosis (Babesia microti): case report and chemotherapeutic trials in hamsters","volume":"88","author":"Miller","year":"1978","journal-title":"Ann Intern Med"},{"key":"2024011216395806300_jiad315-B44","first-page":"69","volume-title":"8-Aminoquinolines: primaquine and tafenoquine","author":"Waters","year":"2012"},{"key":"2024011216395806300_jiad315-B45","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41420-020-00343-6","article-title":"The anti-malarial drug atovaquone potentiates platinum-mediated cancer cell death by increasing oxidative stress","volume":"6","author":"Coates","year":"2020","journal-title":"Cell Death Discov"},{"key":"2024011216395806300_jiad315-B46","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.ijpara.2012.07.001","article-title":"The species specificity of immunity generated by live whole organism immunisation with erythrocytic and pre-erythrocytic stages of rodent malaria parasites and implications for vaccine development","volume":"42","author":"Inoue","year":"2012","journal-title":"Int J Parasitol"},{"key":"2024011216395806300_jiad315-B47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171826","article-title":"Chemoprophylaxis with sporozoite immunization in P. knowlesi rhesus monkeys confers protection and elicits sporozoite-specific memory T cells in the liver","volume":"12","author":"Pichyangkul","year":"2017","journal-title":"PLoS One"},{"key":"2024011216395806300_jiad315-B48","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-021-03684-z","article-title":"Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity","volume":"595","author":"Mwakingwe-Omari","year":"2021","journal-title":"Nature"},{"key":"2024011216395806300_jiad315-B49","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s12916-017-0923-4","article-title":"Modest heterologous protection after Plasmodium falciparum sporozoite immunization: a double-blind randomized controlled clinical trial","volume":"15","author":"Walk","year":"2017","journal-title":"BMC Med"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiad315\/54943643\/jiad315.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/229\/1\/161\/55572145\/jiad315.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/229\/1\/161\/55572145\/jiad315.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T18:13:39Z","timestamp":1705083219000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/229\/1\/161\/7505227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,3]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,3]]},"published-print":{"date-parts":[[2024,1,12]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiad315","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1,15]]},"published":{"date-parts":[[2024,1,3]]}}}